Literature DB >> 6617725

Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.

F Heller, C Harvengt.   

Abstract

Ten male, normolipaemic, non-obese subjects were given clofibrate 2 g daily, fenofibrate 300 mg daily, bezafibrate 600 mg daily and probucol 1 g daily for eight days, in a crossover study with a wash-out period of 4-8 weeks between each drug regimen. Clofibrate, fenofibrate and bezafibrate caused a significant decrease in serum triglycerides, total cholesterol and LDL-cholesterol concentrations. Probucol caused a significant increase in serum LDL-cholesterol concentration. Serum HDL-cholesterol concentration was significantly increased by bezafibrate and significantly decreased by probucol. All drugs but probucol led to a significant rise in the activity of the plasma lipoprotein lipase; there was not a significant increase in the activity of plasma hepatic lipase after any drug. The activity of plasma lecithin: cholesterol acyltransferase was significantly increased by fenofibrate and probucol. Analysis of the correlations between serum lipids and plasma lipolytic enzymes suggests that the mechanism of the hypolipidaemic action of clofibrate and bezafibrate might be related to increased catabolism of triglyceride-rich particles; that of fenofibrate and probucol was less clear and might be multifactorial in origin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6617725     DOI: 10.1007/bf00544015

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  33 in total

1.  The effect of treatment with clofibrate on hepatic triglyceride and lipoprotein lipase activities of post heparin plasma in male patients with hyperlipoproteinemia.

Authors:  J Boberg; M Boberg; R Gross; S Grundy; J Augustin; V Brown
Journal:  Atherosclerosis       Date:  1977-08       Impact factor: 5.162

2.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

3.  Plasma clofibric acid (CPIB) levels induced by three marketed compounds releasing clofibric acid, in volunteers.

Authors:  C Harvengt; J P Desager
Journal:  Int J Clin Pharmacol Biopharm       Date:  1977-01

4.  Nine years of treatment with probucol.

Authors:  D McCaughan
Journal:  Artery       Date:  1982

5.  Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters.

Authors:  B Vessby; H Lithell; K Hellsing; A M Ostlund-Lindqvist; I B Gustafsson; J Boberg; H Ledermann
Journal:  Atherosclerosis       Date:  1980-10       Impact factor: 5.162

6.  [Probucol: chemical structure, physical properties and assay methods (author's transl)].

Authors:  P Pignard
Journal:  Nouv Presse Med       Date:  1980-10-30

7.  [Plasma levels of probucol in man after single and repeated oral doses (author's transl)].

Authors:  J F Heeg; H Tachizawa
Journal:  Nouv Presse Med       Date:  1980-10-30

8.  Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate.

Authors:  B Vessby; H Lithell; H Ledermann
Journal:  Atherosclerosis       Date:  1982-07       Impact factor: 5.162

9.  Increase of the lipoprotein-lipase activity in human skeletal muscle during clofibrate administration.

Authors:  H Lithell; J Boberg; K Hellsing; G Lundqvist; B Vessby
Journal:  Eur J Clin Invest       Date:  1978-04       Impact factor: 4.686

10.  Clofibrate increases lipoprotein-lipase activity in adipose tissue of hypertriglyceridaemic patients.

Authors:  K G Taylor; G Holdsworth; D J Galton
Journal:  Lancet       Date:  1977-11-26       Impact factor: 79.321

View more
  22 in total

1.  Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice.

Authors:  Silvia Bijland; Elsbet J Pieterman; Annemarie C E Maas; José W A van der Hoorn; Marjan J van Erk; Jan B van Klinken; Louis M Havekes; Ko Willems van Dijk; Hans M G Princen; Patrick C N Rensen
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

2.  Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study.

Authors:  Mary K Wojczynski; Guimin Gao; Ingrid Borecki; Paul N Hopkins; Laurence Parnell; Chao-Qiang Lai; Jose M Ordovas; B Hong Chung; Donna K Arnett
Journal:  J Lipid Res       Date:  2010-08-19       Impact factor: 5.922

Review 3.  Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.

Authors:  J A Balfour; D McTavish; R C Heel
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

4.  PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene.

Authors:  K Schoonjans; J Peinado-Onsurbe; A M Lefebvre; R A Heyman; M Briggs; S Deeb; B Staels; J Auwerx
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

Review 5.  New Era of Lipid-Lowering Drugs.

Authors:  Philip J Barter; Kerry-Anne Rye
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

6.  Combination treatment with cholestyramine and bezafibrate for heterozygous familial hypercholesterolaemia.

Authors:  L D Curtis; A C Dickson; K L Ling; J Betteridge
Journal:  BMJ       Date:  1988-07-16

7.  Differences in the response of Sprague-Dawley and Lewis rats to bezafibrate: the hypolipidemic effect and the induction of peroxisomal enzymes.

Authors:  J Pill; A Völkl; F Hartig; H D Fahimi
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

Review 8.  Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.

Authors:  J P Monk; P A Todd
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

9.  Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb.

Authors:  S Bertolini; N Elicio; A Daga; M L Degl'Innocenti; R Balestreri; M G Fusi; A M Cotta Ramusino; A Carozzi
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  High-density lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate.

Authors:  K Saku; B Zhang; S Jimi; H Bai; K Hirata; N Sasaki; R Liu; K Arakawa
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.